Voyager Therapeutics (VYGR) Non-Current Deffered Revenue (2014 - 2025)

Voyager Therapeutics has disclosed Non-Current Deffered Revenue across 12 years of filings, most recently posting $1.5 million for Q3 2025.

• Non-Current Deffered Revenue for Q3 2025 came in at $1.5 million, down 87.9% year-over-year; the trailing twelve-month figure through Sep 2025 was $1.5 million (down 87.9% YoY), and the FY2024 annual result was $6.0 million, down 81.45% from the prior year.
• Non-Current Deffered Revenue came in at $1.5 million for Q3 2025 at Voyager Therapeutics, down from $2.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $78.9 million in Q1 2023 to a low of $1.5 million in Q3 2025.
• The 5-year median for Non-Current Deffered Revenue is $12.2 million (2024), against an average of $20.7 million.
• Across the five-year window, Non-Current Deffered Revenue soared 833.51% in 2023 and slumped 87.9% in 2025, its largest moves.
• Voyager Therapeutics' Non-Current Deffered Revenue stood at $8.2 million in 2021, then decreased by 21.44% to $6.4 million in 2022, then jumped by 401.69% to $32.4 million in 2023, then tumbled by 81.45% to $6.0 million in 2024, then plunged by 75.5% to $1.5 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $1.5 million (Q3 2025), $2.6 million (Q2 2025), and $4.8 million (Q1 2025), per Business Quant data.